Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
Want to see AU:ATH full AI Analyst Report?
ATH Stock Chart & Stats
AU$0.01
>-AU$0.01(-10.00%)
At close: 4:00 PM EST
AU$0.01
>-AU$0.01(-10.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume25.42M
Average Volume (3M)16.33M
Market Cap
AU$119.63M
Enterprise ValueAU$70.59M
Total Cash (Recent Filing)AU$49.20M
Total Debt (Recent Filing)AU$163.91K
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding10,875,416,000
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.01Price Target Upside0.00%
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$3.30M
Bulls Say, Bears Say
Bulls Say
Proprietary Therapeutic PlatformAlterity’s focus on proprietary small‑molecule iron‑modulating compounds and a clear clinical target (MSA) creates a durable scientific differentiation. A specialized, disease‑modifying approach can form a high barrier to entry, support targeted development pathways, and enable valuable licensing or partnership optionality if clinical data advance.
Robust Top-line GrowthA 46% reported revenue increase shows the company can grow top-line receipts—whether from partnerships, grants or milestone income—which supports ongoing R&D investment. Durable revenue expansion improves operational flexibility and helps extend the runway for clinical programs versus peers with flat or declining receipts.
Very Low Financial LeverageMinimal debt reduces insolvency and interest burdens, preserving financial optionality through long clinical cycles. A strong equity base provides balance sheet resilience, enabling management to prioritize R&D and strategic partnerships rather than servicing leverage, which is important for multi‑year drug development timelines.
Bears Say
No Recurring Product RevenueReliance on capital raises rather than product sales is structurally limiting: it creates continual financing and dilution risk and prevents self-sustaining cash generation. Until commercialized therapies or long‑term licensing streams exist, the business model depends on external funding, constraining strategic flexibility.
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow undermines the company’s ability to fund clinical programs internally, increasing dependence on external financing. Over months this raises dilution risk and may force management to prioritize short‑term financing outcomes over optimal long‑term R&D sequencing and partnerships.
Sustained Unprofitability & Negative ROENegative margins and a deeply negative ROE signal the company cannot currently convert revenue into shareholder returns. This structural unprofitability reduces investor confidence and limits reinvestment capacity, meaning long‑term viability depends on achieving successful clinical milestones or transformational partnerships.
Alterity Therapeutics News
ATH FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is AU$119.63M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 298 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.001 earnings per share for the quarter, the consensus estimate of -AU$0.001 by AU$0.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently same.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of -AU$0.001 in its last earnings report, expectations of -AU$0.001. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.01 (0.00% )
AU$0.01 (0.00% )
Blogger Sentiment
Bullish
AU:ATH Sentiment 96%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics (ATH) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, primarily targeting conditions such as Parkinson's disease and Alzheimer's disease. The company leverages its proprietary drug discovery platform to identify and develop small molecule therapies aimed at modifying disease progression and improving patient outcomes. Alterity is dedicated to advancing its clinical programs and expanding its pipeline of novel treatments to address significant unmet medical needs in the neurology sector.
ATH Stock 12 Month Forecast
Average Price Target
AU$0.01
▲(0.00% Upside)
Technical Analysis
Actinogen Medical
―
Cynata Therapeutics Limited
―
Tryptamine Therapeutics
―
Living Cell Technologies
―
Neuren Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---